Fresenius Medical Care Partners with Mexican Health Authorities to Enhance Dialysis Access

Fresenius Medical Care's Groundbreaking Initiative in Mexico

Fresenius Medical Care (FME), a global leader in renal care solutions, has embarked on a significant collaboration with Mexico's Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE) to enhance the availability of cutting-edge dialysis treatments for the region's population. This initiative marks a pivotal advancement in the healthcare options accessible to patients suffering from chronic kidney disease (CKD) in the country.

Expansion of High-Volume Hemodiafiltration Therapy

As part of this partnership, Fresenius Medical Care will roll out High-Volume Hemodiafiltration (HighVolumeHDF) therapy in seven out of ten CCINSHAE centers across Mexico. By developing a tailored pilot program, the initiative aims to provide hemodialysis therapies specifically for low-income patients lacking medical coverage. This move comes at a crucial time when kidney diseases are on the rise, impacting millions worldwide.

Under a two-year agreement, the installation of 150 Fresenius Medical Care 5008S CorDiax machines will take place in participating renal treatment centers located in Mexico City and its metropolitan area. Edgar Robles, the Managing Director of Care Enablement Commercial Operations at Fresenius Medical Care Mexico, stated, "This groundbreaking pilot program aims to provide high-quality treatments to chronic kidney disease patients that are often out of their financial reach."

Improving Patient Outcomes and Access

The innovative HighVolumeHDF therapy has established itself as a superior option compared to traditional hemodialysis treatments. Clinical studies, including the renowned CONVINCE trial, demonstrate that HighVolumeHDF can decrease all-cause mortality rates significantly for patients compared to standard treatment methods. The initial phase of this initiative has already proven successful, with 240 new CCINSHAE patients receiving HighVolumeHDF therapy, along with an additional 410 patients who transitioned from conventional hemodialysis to this advanced therapy.

This project not only reflects Fresenius Medical Care's dedication to serving the underserved populations in Mexico but also aligns with their broader commitment to enhancing the overall quality of dialysis services. Robles emphasized, "Our objective is to raise standards in dialysis care, thereby improving the quality of life for patients while providing efficient operational solutions for healthcare providers."

Future Initiatives and Expansion Plans

Fresenius Medical Care's mission is to bring this life-saving therapy to all markets where it is not yet available, including the United States. Recently, the company received FDA clearance for its 5008X Hemodialysis System, which is anticipated to play a crucial role in the U.S. commercialization of HighVolumeHDF.

In May 2025, Fresenius secured FDA approval for an updated version of its hemodiafiltration-capable 5008X CAREsystem, supporting the company's step towards a significant commercial launch planned for 2026. This initiative positions Fresenius Medical Care to lead the way in transforming renal care not just in Mexico, but globally.

Through its comprehensive network of 3,675 dialysis clinics, Fresenius Medical Care is dedicated to providing treatment for approximately 299,000 patients around the world. The organization remains at the forefront of developing treatments that align with the needs of patients with renal diseases.

For further information about Fresenius Medical Care, visit their website at www.freseniusmedicalcare.com.